At Oxidien™, we are dedicated to bringing life-changing products to patients in need. We create best-in-class enzyme-based pharmaceuticals. Using innovative research, open-minded conviction, and passionate diligence Oxidien™ is committed to advancing the standard of care.
The name Oxidien™ stems from the dietary culprit (oxalate) and the patient indications we serve: “Ox” for oxalate, “idi” for idiopathic and “en” for enteric.
There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3 .
- IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones 1, 4, 5 .
- EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure.
OX-1 is a novel oxalate decarboxylase (OxDC) enzyme developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. OX-1 demonstrates stability in a wide pH range including very acidic environments; thus, can effectively degrade oxalate in the gastrointestinal tract, in particular the stomach.
BSBA, CCRP, CCRA
Ira W. Klimberg